And you take the wordings of the ann with100% certainty that it will happen ? The auditor's report is more recent. There is a reason why they put this line ' the company may be required to raise further capital to facilitate this acquisition' in their report. It means they are not satisfied with the announced funding structure of the acquisition. Be critical.
They are having a margin of 10%. Assuming no significant gap in the debtors collection days and supplier payments terms, they need to make a 120m sales to cover the 12m cash component of acquisition.
Debt funding - no debt facility in place per annual report (none as at 30 June 2019. No mention as well in the subsequent events relating to the Company obtaining one after 30 June 2019).
Cash of 7.8m as at 30 June 2019 - sound business practice dictates that you should not use a major part of your cash to invest in long term asset.
So, where do you think the funding will be coming from?
- Forums
- ASX - By Stock
- JAT
- Ann: Appendix 4E & Full Year Statutory Accounts
Ann: Appendix 4E & Full Year Statutory Accounts, page-36
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add JAT (ASX) to my watchlist
(20min delay)
|
|||||
Last
49.3¢ |
Change
0.008(1.55%) |
Mkt cap ! $41.00M |
Open | High | Low | Value | Volume |
49.3¢ | 49.3¢ | 49.3¢ | $1.231K | 2.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 8000 | 46.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.5¢ | 30062 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8000 | 0.460 |
3 | 59950 | 0.450 |
1 | 37647 | 0.425 |
1 | 16477 | 0.415 |
2 | 20714 | 0.410 |
Price($) | Vol. | No. |
---|---|---|
0.495 | 30062 | 2 |
0.500 | 1097 | 1 |
0.525 | 223 | 1 |
0.540 | 33334 | 1 |
0.550 | 11677 | 1 |
Last trade - 13.03pm 15/11/2024 (20 minute delay) ? |
Featured News
JAT (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online